- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Oncology
Volume 2010 (2010), Article ID 351908, 11 pages
Molecular Therapeutic Targets for Glioma Angiogenesis
1Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba Ibaraki 305-8575, Japan
2Regenerative Medicine/Stem Cell Biology, Institute of Basic Medical Science, University of Tsukuba, Tsukuba Ibaraki 305-8575, Japan
Received 28 October 2009; Revised 9 December 2009; Accepted 27 January 2010
Academic Editor: Arkadiusz Dudek
Copyright © 2010 Shingo Takano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. S. Kerbel, “Tumor angiogenesis,” The New England Journal of Medicine, vol. 358, no. 19, pp. 2039–2049, 2008.
- P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” The New England Journal of Medicine, vol. 359, no. 5, pp. 492–507, 2008.
- G. Bergers and D. Hanahan, “Modes of resistance to anti-angiogenic therapy,” Nature Reviews Cancer, vol. 8, no. 8, pp. 592–603, 2008.
- S. Takano, Y. Yoshii, S. Kondo, et al., “Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients,” Cancer Research, vol. 56, no. 9, pp. 2185–2190, 1996.
- S. Takano, K. Tsuboi, Y. Tomono, Y. Mitsui, and T. Nose, “Tissue factor, osteopontin, integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression,” British Journal of Cancer, vol. 82, no. 12, pp. 1967–1973, 2000.
- S. Takano, K. Tsuboi, A. Matsumura, Y. Tomono, Y. Mitsui, and T. Nose, “Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors,” Journal of Cancer Research and Clinical Oncology, vol. 126, no. 3, pp. 145–152, 2000.
- S. Takano, H. Kamiyama, K. Tsuboi, and A. Matsumura, “Angiogenesis and antiangiogenic therapy for malignant gliomas,” Brain Tumor Pathology, vol. 21, no. 2, pp. 69–73, 2004.
- S. Takano, S. Gately, M. E. Neville, et al., “Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator,” Cancer Research, vol. 54, no. 10, pp. 2654–2660, 1994.
- S. Takano, S. Gately, H. Engelhard, A. M. C. Tsanaclis, and S. Brem, “Suramin inhibits glioma cell proliferation in vitro and in the brain,” Journal of Neuro-Oncology, vol. 21, no. 3, pp. 189–201, 1994.
- J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, et al., “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4722–4729, 2007.
- S. Ananthnarayan, J. Bahng, J. Roring, et al., “Time course of imaging changes of GBM during extended bevacizumab treatment,” Journal of Neuro-Oncology, vol. 88, no. 3, pp. 339–347, 2008.
- S. Takano, K. Tsuboi, A. Matsumura, and T. Nose, “Therapeutic combination of anti-VEGF antibody and ACNU chemotherapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts,” Neuro-Oncology, vol. 5, no. 1, pp. 1–7, 2003.
- C. Folkins, S. Man, P. Xu, et al., “Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor-like cell fraction in glioma xenograft tumors,” Cancer Research, vol. 67, no. 8, pp. 3560–3564, 2007.
- R. J. Gilbertson and J. N. Rich, “Making a tumour's bed: glioblastoma stem cells and the vascular niche,” Nature Reviews Cancer, vol. 7, no. 10, pp. 733–736, 2007.
- A. Narayana, J. G. Golfinos, I. Fischer, et al., “Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 2, pp. 383–389, 2008.
- A. D. Norden, G. S. Young, K. Setayesh, et al., “Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence,” Neurology, vol. 70, no. 10, pp. 779–787, 2008.
- R. M. Zuniga, R. Torcuator, R. Jain, et al., “Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan,” Journal of Neuro-Oncology, vol. 91, no. 3, pp. 329–336, 2009.
- S. Sathornsumetee, Y. Cao, J. E. Marcello, et al., “Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 271–278, 2008.
- D. Hanahan, G. Bergers, and E. Bergsland, “Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice,” Journal of Clinical Investigation, vol. 105, no. 8, pp. 1045–1047, 2000.
- H. Kamiyama, S. Takano, K. Tsuboi, and A. Matsumura, “Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1a)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 4, pp. 205–213, 2005.
- R. Stupp, W. P. Mason, M. J. van den Bent, et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005.
- A. Lai, E. Filka, B. McGibbon, et al., “Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 5, pp. 1372–1380, 2008.
- A. Narayana, P. Kelly, J. Golfinos, et al., “Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival,” Journal of Neurosurgery, vol. 110, no. 1, pp. 173–180, 2009.
- V. Mathieu, N. de Neve, M. le Mercier, et al., “Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model,” Neoplasia, vol. 10, no. 12, pp. 1383–1392, 2008.
- S. Baruchel, M. Diezi, D. Hargrave, et al., “Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours,” European Journal of Cancer, vol. 42, no. 14, pp. 2335–2342, 2006.
- D. S. Kong, J. I. Lee, W. S. Kim, et al., “A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma,” Oncology Reports, vol. 16, no. 5, pp. 1117–1121, 2006.
- B. Croix, C. Rago, V. Velculescu, et al., “Genes expressed in human tumor endothelium,” Science, vol. 289, no. 5482, pp. 1197–1202, 2000.
- C. Charalambous, F. M. Hofman, and T. C. Chen, “Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells,” Journal of Neurosurgery, vol. 102, no. 4, pp. 699–705, 2005.
- S. Miebach, S. Grau, V. Hummel, P. Rieckmann, J.-C. Tonn, and R. H. Goldbrunner, “Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades,” Journal of Neuro-Oncology, vol. 76, no. 1, pp. 39–48, 2006.
- M. Nagano, T. Yamashita, H. Hamada, et al., “Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood,” Blood, vol. 110, no. 1, pp. 151–160, 2007.
- A. D. Norden, J. Drappatz, and P. Y. Wen, “Novel anti-angiogenic therapies for malignant gliomas,” The Lancet Neurology, vol. 7, no. 12, pp. 1152–1160, 2008.
- I. Noguera-Troise, C. Daly, N. J. Papadopoulos, et al., “Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis,” Nature, vol. 444, no. 7122, pp. 1032–1037, 2006.
- J. Ridgway, G. Zhang, Y. Wu, et al., “Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis,” Nature, vol. 444, no. 7122, pp. 1083–1087, 2006.
- M. Yan and G. D. Plowman, “Delta-like 4/notch signaling and its therapeutic implications,” Clinical Cancer Research, vol. 13, no. 24, pp. 7243–7246, 2007.
- D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall, “Targeting Urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT,” Journal of the National Cancer Institute, vol. 94, no. 8, pp. 597–606, 2002.
- W. A. Hall and D. A. Vallera, “Efficacy of antiangiogenic targeted toxins against glioblastoma multiforma,” Neurosurg Focus, vol. 20, no. 4, pp. 1–6, 2006.